Publications: 124 in 2026-04. +33.8% share of all MeSH-indexed PubMed records vs the same month last year (95 in 2025-04).
PublicationsPubMed
1242026-04
+33.8% share of all MeSH-indexed PubMed records vs same month last year (95 in 2025-04)provisional · settling
0.11% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 4 in 2026-09. No percentage shown. No percentage shown: both months are under 15 records. The count is ranked in its own history instead. Clinical trials: latest count 4 is in the 36th percentile, in its typical range, versus 321 months since 2000.
Clinical trialsClinicalTrials.gov
42026-09
36th percentilein its typical range, versus 321 months since 2000low volume
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 21 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 21 is in the 28th percentile, running low, versus 16-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
212026-09
28th percentilerunning low, versus 16-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 100 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 100 is in the 84th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
1002026-09
84th percentilerunning high, versus 16-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 22 in 2026-09. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 22 is in the 97th percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
222026-09
97th percentilenear its historical high, versus 16-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 124 is in the 46th percentile, in its typical range, versus 320 months since 2000.
46thpercentile
in its typical range
124/mo · higher than 46% of 320 months since 2000
Clinical trials
Clinical trials: latest count 4 is in the 36th percentile, in its typical range, versus 321 months since 2000.
36thpercentile
in its typical range
4/mo · higher than 30% of 321 months since 2000
NIH grantsprovisional
NIH grants: latest count 21 is in the 28th percentile, running low, versus 16-mo window (2025 to 2026) (provisional, short baseline).
28thpercentile
running low
21/mo · higher than 25% of 16-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 100 is in the 84th percentile, running high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
84thpercentile
running high
100/mo · higher than 81% of 16-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 22 is in the 97th percentile, near its historical high, versus 16-mo window (2025 to 2026) (provisional, short baseline).
97thpercentile
near its historical high
22/mo · higher than 94% of 16-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 16 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 321 mo; NIH grants 2025 to 2026 · 16 mo; Patents 2025 to 2026 · 16 mo; Preprints 2025 to 2026 · 16 mo.
Publications2000 to 2026 · 320 mopeak 286/mo
Clinical trials2000 to 2026 · 321 mopeak 24/mo
NIH grants2025 to 2026 · 16 mobackfill pendingpeak 100/mo
Patents2025 to 2026 · 16 mobackfill pendingpeak 118/mo
Preprints2025 to 2026 · 16 mobackfill pendingpeak 22/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2023-08..2026-07
2%of works have an industry affiliation
Inserm222
University of North Carolina at Chapel Hill178
University of Washington149
University of Colorado Denver133
Cystic Fibrosis Foundation119
Clinical trials
Lead sponsors · 2023-10..2026-09
25%industry-led in 2026-09
Vertex Pharmaceuticals IncorporatedIndustry11
Hospices Civils de LyonAcademic/other7
Assiut UniversityAcademic/other6
Hacettepe UniversityAcademic/other4
Indiana UniversityAcademic/other4
NIH grants
Funded institutions · 2025-06..2026-09
646awards in window
UNIV OF NORTH CAROLINA CHAPEL HILLNC · $19.5M · P30/U5437
UNIVERSITY OF IOWAIA · $18.3M · P30/R0136
EMORY UNIVERSITYGA · $13.5M · R01/P3030
DARTMOUTH COLLEGENH · $13.8M · P30/R0126
CINCINNATI CHILDRENS HOSP MED CTROH · $13.3M · P30/R0124
Would you read a monthly digest for Cystic Fibrosis?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Cystic Fibrosis. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Cystic Fibrosis.
How we map "Cystic Fibrosis"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Cystic Fibrosis"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10